PHILADELPHIA -- Steve Fluharty, the University of Pennsylvania’s senior vice provost for research, is participating in a new congressional program that will highlight federally funded science projects. Called the “Golden Goose Awards,” not just any projects will do; the program exists to draw attention to the sometimes-serendipitous nature of scientific progress.
Bruce Levine and Carl June of the Perelman School of Medicine are highlighted for their gene therapy research.
Mark Duggan of the Wharton School is cited for a research paper about unemployment.
NSAIDs and Cardiovascular Risk Explained, According to Studies From Penn's Perelman School of Medicine
After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it.
Genetically Modified T Cell Therapy Shown to Be Safe, Lasting in Penn Medicine Study of HIV Patients
HIV patients treated with genetically modified T cells remain healthy up to 11 years after initial therapy, researchers from the Perelman School of Medicine at the University of Pennsylvania report in the new issue of Science Translational Medicine. The results provide a framework for the use of this type of gene therapy as a powerful weapon in the treatment of HIV, cancer, and a wide variety of other diseases.
Penn’s Center for High Impact Philanthropy Launches Development of Child-Survival Tool Kit for Donors
PHILADELPHIA — Having a virtual copy of a patient’s blood in a computer would be a boon to researchers and doctors. They could examine a simulated heart attack caused by blood clotting in a diseased coronary artery and see if a drug like aspirin would be effective in reducing the size of such a clot.
Penn Study Confirms 2 Treatments for Age-related Macular Degeneration Provide Equal Vision Improvements
Two drugs commonly used to treat age-related macular degeneration (AMD) yield similar improvements in vision for patients receiving treatments on a monthly or as-needed basis, according to a study from researchers at the Center for Preventive Ophthalmology and Biostatistics (CPOB) at the Perelman School of Medicine at the University of Pennsylvania.